This is a very clear exposition of the status of Pharma in China. One point to add is that there has been a flood of global biopharmaceutical companies in-licensing drugs from Chinese biotechs of late. This is noteworthy as we're talking new drugs (as opposed to cheap generics) and effectively China Inc is creating a pool of new assets that are competing (and in many ways displacing) those developed by Western Biotechs. They are also available at a clear discount. This phenomenon mirrors developments in other high tech arenas (such as AI).
This is a very clear exposition of the status of Pharma in China. One point to add is that there has been a flood of global biopharmaceutical companies in-licensing drugs from Chinese biotechs of late. This is noteworthy as we're talking new drugs (as opposed to cheap generics) and effectively China Inc is creating a pool of new assets that are competing (and in many ways displacing) those developed by Western Biotechs. They are also available at a clear discount. This phenomenon mirrors developments in other high tech arenas (such as AI).
Indeed! More on this to come!